The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test, a companion diagnostic for erlotinib (Tarceva). This is the first FDA-approved companion diagnostic that detects epidermal growth factor receptor (EGFR) gene mutations, which are present in approximately 10% of...
Frozen balls of ice can safely kill cancerous tumors that have spread to the lungs, according to the first prospective multicenter trial of cryoablation. The results were presented on April 14, 2013, at the Society of Interventional Radiology’s 38th Annual Scientific Meeting in New Orleans....
The chances of developing lung cancer associated with asbestos exposure, asbestosis, and smoking are dramatically increased when these three risk factors are combined, and quitting smoking significantly reduces the risk of developing lung cancer after long-term asbestos exposure, according to a new ...
The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number 1 cancer killer in the United States and abroad. Now, for the first time after a decade of biomarker testing in lung cancer, a uniform approach for testing for the EGFR mutation and ALK...
Poly (ADP-ribose) polymerase (PARP) inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for...
Physicians who care for lung cancer patients recognize the importance of tobacco cessation but often do not provide cessation assistance to their patients, according to a recent study published in the Journal of Thoracic Oncology. Survey Details An online survey was conducted in 2012 by the...
New results from a large observational follow-up study conducted in Shanghai, China, indicate that women with lung cancer who consumed more soy food prior to their cancer diagnosis lived longer than those who consumed less soy. The study, published March 25 in the Journal of Clinical Oncology,...
A drug that indirectly impairs the function of several cancer-driving proteins, including anaplastic lymphoma kinase (ALK), may be an effective new treatment for patients with ALK-positive non–small cell lung cancer (NSCLC). The drug, ganetespib, may also be effective for treating patients...
Molecular driven therapeutic targets have resulted in a paradigm shift in the treatment of advanced lung adenocarcinoma. However, in early non–small cell lung cancer (NSCLC), surgical resection remains the treatment of choice with adjuvant chemotherapy. In a recent study published in the...
Combatting the tobacco industry’s tactics in the world’s poorest countries as well as ensuring the best cancer vaccines are available to those most in need are key in order to reduce the number of cancer deaths worldwide, according to a new report published in the journal Science...
Patients with non–small cell lung cancer (NSCLC) have improved survival outcomes if they are taking beta-blockers while receiving radiotherapy, according to a study of 722 patients recently published in Annals of Oncology. Researchers at the University of Texas MD Anderson Cancer Center in...